Literature DB >> 15976725

[New etiological concepts in uveitis].

B Bodaghi1.   

Abstract

Uveitis remains an important cause of visual impairment, particularly in young patients. Idiopathic forms of intraocular inflammation should no longer be regarded as a presumed clinical entity, and the ophthalmologist must reconsider the specific etiology of primary uveitis when the clinical examination does not yield a definitive diagnosis or when the course of the disease on corticosteroids remains atypical. Laboratory tests based on serum analysis have limited value and should not be considered as diagnostic proof in different clinical presentations. The diagnostic management of infectious uveitis has been greatly improved by the use of molecular techniques applied to ocular fluids and tissues. Polymerase chain reaction (PCR) technology is a powerful tool that should be proposed in atypical cases of uveitis or retinitis of unclear but potentially infectious origin. This strategy is a major step before using unconventional and new immunomodulatory agents such as anti-TNF-alpha molecules. Under strict experimental conditions including adequate testing to rule out a possible contamination, PCR and its variants have changed our practical approach to intraocular inflammatory disorders and have provided new details for the understanding of infectious uveitis. The concept of pathogen-induced intraocular inflammation can be revisited in the light of molecular data obtained after anterior chamber paracentesis or diagnostic vitrectomy.

Entities:  

Mesh:

Year:  2005        PMID: 15976725     DOI: 10.1016/s0181-5512(05)81095-2

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  2 in total

1.  [Epstein-Barr virus associated acute retinal necrosis].

Authors:  D Roquelaure; S Harbarth; J S Schutz; G Thumann; A Chronopoulos
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

2.  Aqueous humor polymerase chain reaction in uveitis - utility and safety.

Authors:  Argyrios Chronopoulos; Daniel Roquelaure; Georges Souteyrand; Jörg Dieter Seebach; James Scott Schutz; Gabriele Thumann
Journal:  BMC Ophthalmol       Date:  2016-10-28       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.